Standard Document
Third Edition
Method Evaluation

CLSI EP19

A Framework for Using CLSI Documents to Evaluate Medical Laboratory Test Methods

Discover the Test Life Phases Model in this essential report, which provides a clear path to CLSI evaluation protocols. Whether you're working with commercially manufactured or laboratory-developed test methods, this guide will help you establish and implement them with confidence.

 

October 10, 2022
Paula Ladwig, MS, MT(ASCP); Jennifer Rychert, PhD, D(ABMM)

{{FormatPrice(currentPrice)}}

Free

{{FormatPrice(nonMemberPrice)}} List Price
This is your member pricing.
Notify Me About New Editions
Overview of Changes

This report replaces the previous edition of the approved report EP19-Ed2, published in 2015. The original intent of EP19 to provide a useful, high-level guide has not changed. Several changes were made in this edition, including: 

• Introducing CLSI electronic product Method Navigator 

• Updating the figures and flow chart 

• Enhancing discussion of the concept of risk management as an integral part of the Test Life Phases Model 

• Updating Special Cases section

Scope

EP19 is organized around the Test Life Phases Model, which is the concept that all test methods undergo establishment by a developer, followed by implementation by the end user, all sequentially. For the purposes of EP19, the term "test method" includes the processes, reagents, supplies, calibrators, control material, hardware, software, and any other components that make up a test. EP19 describes the considerations and processes for planning, performing, and documenting test method evaluations by referring users to the appropriate CLSI EP documents, along with other related documents and resources when applicable. Effective use of EP19 is based on the premise that both the developer and the end user have a QMS in place with appropriate controls over all essential processes, including personnel, environment, general processes, and documentation. Users should refer to CLSI electronic product Method Navigator in conjunction with EP19. 

Because CLSI documents are regularly updated, the EP documents can be considered generally accepted good practice for how test methods should be evaluated. EP19 provides general reference on the specific CLSI documents that are useful for test method evaluations and provides considerations for how users could most effectively benefit from this information. EP19 users should refer to the referenced CLSI documents for sufficient details to plan, perform, and interpret the evaluations correctly.

Product Details
EP19Ed3E
978-1-68440-165-9
48
Additional Details

This document is available in electronic format only.

The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.

Supporting Resources
CLSI EP15IG
User Verification of Precision Implementation Guide
Companion
Method Evaluation
Free
Overview of Changes

This report replaces the previous edition of the approved report EP19-Ed2, published in 2015. The original intent of EP19 to provide a useful, high-level guide has not changed. Several changes were made in this edition, including: 

• Introducing CLSI electronic product Method Navigator 

• Updating the figures and flow chart 

• Enhancing discussion of the concept of risk management as an integral part of the Test Life Phases Model 

• Updating Special Cases section

Scope

EP19 is organized around the Test Life Phases Model, which is the concept that all test methods undergo establishment by a developer, followed by implementation by the end user, all sequentially. For the purposes of EP19, the term "test method" includes the processes, reagents, supplies, calibrators, control material, hardware, software, and any other components that make up a test. EP19 describes the considerations and processes for planning, performing, and documenting test method evaluations by referring users to the appropriate CLSI EP documents, along with other related documents and resources when applicable. Effective use of EP19 is based on the premise that both the developer and the end user have a QMS in place with appropriate controls over all essential processes, including personnel, environment, general processes, and documentation. Users should refer to CLSI electronic product Method Navigator in conjunction with EP19. 

Because CLSI documents are regularly updated, the EP documents can be considered generally accepted good practice for how test methods should be evaluated. EP19 provides general reference on the specific CLSI documents that are useful for test method evaluations and provides considerations for how users could most effectively benefit from this information. EP19 users should refer to the referenced CLSI documents for sufficient details to plan, perform, and interpret the evaluations correctly.

Additional Details

This document is available in electronic format only.

The U.S. Food and Drug Administration (FDA) has evaluated and recognized this approved-level consensus standard for use in satisfying a regulatory requirement.

Supporting Resources
CLSI EP15IG
User Verification of Precision Implementation Guide
Companion
Method Evaluation
Free